In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals

Loading...
Loading...

In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals APLS, showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 8 1 5 0 0
Last 30D 2 0 0 0 0
1M Ago 4 0 2 0 0
2M Ago 0 0 1 0 0
3M Ago 2 1 2 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis of recent analyst actions unveils how financial experts perceive Apellis Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Eliana Merle UBS Lowers Buy $85.00 $89.00
Joseph Stringer Needham Maintains Buy $85.00 -
Graig Suvannavejh Mizuho Lowers Neutral $52.00 $60.00
Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 -
Joseph Stringer Needham Maintains Buy $85.00 -
Laura Chico Wedbush Lowers Neutral $57.00 $67.00
Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 -
Joseph Stringer Needham Maintains Buy $85.00 -
Graig Suvannavejh Mizuho Maintains Neutral $60.00 $60.00
Anupam Rama JP Morgan Raises Overweight $79.00 $78.00
Eliana Merle UBS Raises Buy $89.00 $87.00
Douglas Tsao HC Wainwright & Co. Maintains Buy $92.00 -
Laura Chico Wedbush Raises Neutral $67.00 $60.00
Graig Suvannavejh Mizuho Raises Neutral $60.00 $49.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
  • Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Apellis Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Apellis Pharmaceuticals analyst ratings.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals: A Financial Overview

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Apellis Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 545.89%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -60.51%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -41.51%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Apellis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.02%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.57.

Understanding the Relevance of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...